584 related articles for article (PubMed ID: 10080600)
1. Comparative outcomes of T-cell-depleted and non-T-cell-depleted allogeneic bone marrow transplantation for chronic myelogenous leukemia: impact of donor lymphocyte infusion.
Sehn LH; Alyea EP; Weller E; Canning C; Lee S; Ritz J; Antin JH; Soiffer RJ
J Clin Oncol; 1999 Feb; 17(2):561-8. PubMed ID: 10080600
[TBL] [Abstract][Full Text] [Related]
2. T-cell depletion plus salvage immunotherapy with donor leukocyte infusions as a strategy to treat chronic-phase chronic myelogenous leukemia patients undergoing HLA-identical sibling marrow transplantation.
Drobyski WR; Hessner MJ; Klein JP; Kabler-Babbitt C; Vesole DH; Margolis DA; Keever-Taylor CA
Blood; 1999 Jul; 94(2):434-41. PubMed ID: 10397710
[TBL] [Abstract][Full Text] [Related]
3. Donor T-lymphocyte infusion for unrelated allogeneic bone marrow transplantation with CD3+ T-cell-depleted graft.
Lee CK; deMagalhaes-Silverman M; Hohl RJ; Hayashi M; Buatti J; Wen BC; Schlueter A; Strauss RG; Gingrich RD
Bone Marrow Transplant; 2003 Jan; 31(2):121-8. PubMed ID: 12621494
[TBL] [Abstract][Full Text] [Related]
4. Toxicity and efficacy of defined doses of CD4(+) donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant.
Alyea EP; Soiffer RJ; Canning C; Neuberg D; Schlossman R; Pickett C; Collins H; Wang Y; Anderson KC; Ritz J
Blood; 1998 May; 91(10):3671-80. PubMed ID: 9573003
[TBL] [Abstract][Full Text] [Related]
5. T-cell--depleted allogeneic bone marrow transplantation followed by donor lymphocyte infusion in patients with multiple myeloma: induction of graft-versus-myeloma effect.
Alyea E; Weller E; Schlossman R; Canning C; Webb I; Doss D; Mauch P; Marcus K; Fisher D; Freeman A; Parikh B; Gribben J; Soiffer R; Ritz J; Anderson K
Blood; 2001 Aug; 98(4):934-9. PubMed ID: 11493435
[TBL] [Abstract][Full Text] [Related]
6. CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation.
Giralt S; Hester J; Huh Y; Hirsch-Ginsberg C; Rondón G; Seong D; Lee M; Gajewski J; Van Besien K; Khouri I; Mehra R; Przepiorka D; Körbling M; Talpaz M; Kantarjian H; Fischer H; Deisseroth A; Champlin R
Blood; 1995 Dec; 86(11):4337-43. PubMed ID: 7492795
[TBL] [Abstract][Full Text] [Related]
7. Alpha-interferon with very-low-dose donor lymphocyte infusion for hematologic or cytogenetic relapse of chronic myeloid leukemia induces rapid and durable complete remissions and is associated with acceptable graft-versus-host disease.
Posthuma EF; Marijt EW; Barge RM; van Soest RA; Baas IO; Starrenburg CW; van Zelderen-Bhola SL; Fibbe WE; Smit WM; Willemze R; Falkenburg JH
Biol Blood Marrow Transplant; 2004 Mar; 10(3):204-12. PubMed ID: 14993886
[TBL] [Abstract][Full Text] [Related]
8. In relapsed patients after lymphocyte depleted bone marrow transplantation the percentage of donor T lymphocytes correlates well with the outcome of donor leukocyte infusion.
Schattenberg A; Schaap N; Van De Wiel-Van Kemenade E; Bär B; Preijers F; Van Der Maazen R; Roovers E; De Witte T
Leuk Lymphoma; 1999 Jan; 32(3-4):317-25. PubMed ID: 10037029
[TBL] [Abstract][Full Text] [Related]
9. CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors.
Soiffer RJ; Mauch P; Fairclough D; Alyea E; Anderson K; Fisher D; Freedman A; Bartlett-Pandite L; Robertson M; Schlossman R; Gollob J; Marcus K; Murray C; Kuhlman C; Freeman A; Nadler L; Ritz J
Biol Blood Marrow Transplant; 1997 Apr; 3(1):11-7. PubMed ID: 9209736
[TBL] [Abstract][Full Text] [Related]
10. Donor Lymphocyte Infusions for Chronic Myeloid Leukemia Relapsing after Allogeneic Stem Cell Transplantation: May We Predict Graft-versus-Leukemia Without Graft-versus-Host Disease?
Radujkovic A; Guglielmi C; Bergantini S; Iacobelli S; van Biezen A; Milojkovic D; Gratwohl A; Schattenberg AV; Verdonck LF; Niederwieser DW; de Witte T; Kröger N; Olavarria E;
Biol Blood Marrow Transplant; 2015 Jul; 21(7):1230-6. PubMed ID: 25797175
[TBL] [Abstract][Full Text] [Related]
11. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation.
Collins RH; Shpilberg O; Drobyski WR; Porter DL; Giralt S; Champlin R; Goodman SA; Wolff SN; Hu W; Verfaillie C; List A; Dalton W; Ognoskie N; Chetrit A; Antin JH; Nemunaitis J
J Clin Oncol; 1997 Feb; 15(2):433-44. PubMed ID: 9053463
[TBL] [Abstract][Full Text] [Related]
12. Prevention of graft-versus-host disease by selective depletion of CD6-positive T lymphocytes from donor bone marrow.
Soiffer RJ; Murray C; Mauch P; Anderson KC; Freedman AS; Rabinowe SN; Takvorian T; Robertson MJ; Spector N; Gonin R
J Clin Oncol; 1992 Jul; 10(7):1191-200. PubMed ID: 1607923
[TBL] [Abstract][Full Text] [Related]
13. Use of unrelated marrow grafts compensates for reduced graft-versus-leukemia reactivity after T-cell-depleted allogeneic marrow transplantation for chronic myelogenous leukemia.
Hessner MJ; Endean DJ; Casper JT; Horowitz MM; Keever-Taylor CA; Roth M; Flomenberg N; Drobyski WR
Blood; 1995 Nov; 86(10):3987-96. PubMed ID: 7579370
[TBL] [Abstract][Full Text] [Related]
14. Distinct patterns of minimal residual disease associated with graft-versus-host disease after allogeneic bone marrow transplantation for chronic myelogenous leukemia.
Pichert G; Roy DC; Gonin R; Alyea EP; Bélanger R; Gyger M; Perreault C; Bonny Y; Lerra I; Murray C
J Clin Oncol; 1995 Jul; 13(7):1704-13. PubMed ID: 7602361
[TBL] [Abstract][Full Text] [Related]
15. The effect of T cell depletion with Campath-1M on immune reconstitution after chemotherapy and allogeneic bone marrow transplant as treatment for leukaemia.
Lowdell MW; Craston R; Ray N; Koh M; Galatowicz G; Prentice HG
Bone Marrow Transplant; 1998 Apr; 21(7):679-86. PubMed ID: 9578307
[TBL] [Abstract][Full Text] [Related]
16. Donor Lymphocyte Infusion for Relapsed Hematological Malignancies after Unrelated Allogeneic Bone Marrow Transplantation Facilitated by the Japan Marrow Donor Program.
Miyamoto T; Fukuda T; Nakashima M; Henzan T; Kusakabe S; Kobayashi N; Sugita J; Mori T; Kurokawa M; Mori SI
Biol Blood Marrow Transplant; 2017 Jun; 23(6):938-944. PubMed ID: 28219836
[TBL] [Abstract][Full Text] [Related]
17. Allogeneic cell-mediated immunotherapy using donor lymphocytes for prevention of relapse in patients treated with allogeneic bone marrow transplantation for hematological malignancies.
Naparstek E; Nagler A; Or R; Kapelushnik J; Slavin S
Clin Transpl; 1996; ():281-90. PubMed ID: 9286578
[TBL] [Abstract][Full Text] [Related]
18. Donor leukocyte infusions for recurrent hematologic malignancies after allogeneic bone marrow transplantation: impact of infused and residual donor T cells.
Verdonck LF; Petersen EJ; Lokhorst HM; Nieuwenhuis HK; Dekker AW; Tilanus MG; de Weger RA
Bone Marrow Transplant; 1998 Dec; 22(11):1057-63. PubMed ID: 9877267
[TBL] [Abstract][Full Text] [Related]
19. Donor lymphocyte infusions (DLI) in patients with chronic myeloid leukemia following allogeneic bone marrow transplantation.
Bacigalupo A; Soracco M; Vassallo F; Abate M; Van Lint MT; Gualandi F; Lamparelli T; Occhini D; Mordini N; Bregante S; Figari O; Benvenuto F; Sessarego M; Fugazza G; Carlier P; Valbonesi M
Bone Marrow Transplant; 1997 May; 19(9):927-32. PubMed ID: 9156268
[TBL] [Abstract][Full Text] [Related]
20. Donor chimerism does not predict response to donor lymphocyte infusion for relapsed chronic myelogenous leukemia after allogeneic hematopoietic cell transplantation.
Chiorean EG; DeFor TE; Weisdorf DJ; Blazar BR; McGlave PB; Burns LJ; Brown C; Miller JS
Biol Blood Marrow Transplant; 2004 Mar; 10(3):171-7. PubMed ID: 14993882
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
